Drugs / Choline Alfoscerate
Choline Alfoscerate
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02395926 | Oct → Dec 2013 | — | Hyundai Pharmaceutical Co., LTD. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03228498 | May 2017 → Jul 2019 | vascular dementia | Careggi University Hospital | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03249259 | Mar 2016 → Jun 2019 | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT05383183 | Jan 2022 → Jun 2025 | Alzheimer disease | Daewoong Bio Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT05041790 | Sep 2021 → Nov 2024 | cognitive impairment with or without cerebellar ataxia | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 4 | NCT05050604 | Sep 2021 → Nov 2024 | cognitive impairment with or without cerebellar ataxia | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 4 | NCT03441516 | Apr 2018 → Jul 2019 | Alzheimer disease | Yuhan Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT02648906 | Jul 2015 → Nov 2018 | Alzheimer disease | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 4 | NCT01363648 | Nov 2010 → Mar 2013 | cognitive disorder, stroke disorder | Seoul National University Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01388738 Comparator | Jan → Oct 2011 | stroke disorder | Clinical Institute of the Brain, Russia | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05257902 Comparator | Mar 2022 → Mar 2023 | major depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Choline alfoscerate | “Choline alfoscerate(L-alfa glycerylphosphorylcholine) is a natural compound found in the brain and breast.” NCT02395926 ↗ |
| Known as | Alfoscerate de choline | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067974 ↗ |
| Known as | Alfoscerato de colina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067974 ↗ |
| Known as | alpha-glyceryl phosphoryl choline | “Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)” NCT01363648 ↗ |
| Known as | choline alphoscerate | “Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)” NCT01363648 ↗3“Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks” NCT03441516 ↗ |
| Known as | Gliatilin | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067974 ↗ |
| Known as | Glycerophosphocholine | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067974 ↗ |
| Known as | L-alfa glycerylphosphorylcholine | “Choline alfoscerate(L-alfa glycerylphosphorylcholine) is a natural compound found in the brain and breast.” NCT02395926 ↗ |
| Known as | L-Alpha glycerylphosphorylcholine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01388738 ↗ |
| Route | Oral | “choline alphoscerate 1200mg per day and nimodipine 90mg per day given orally” NCT03228498 ↗ |